Stockwinners Market Radar for October 31, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:07 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. The United States and the European Union on Sunday ended a dispute over steel and aluminum tariffs and said they would work on a global arrangement to combat "dirty" production and overcapacity in the industry, Reuters' Jeff Mason and Jan Strupczewski reported. The future EU-U.S. arrangement will be a challenge for China, which produces more than half of the world's steel and which the EU and U.S. accuse of creating overcapacity that is threatening the survival of their own steel industries, the authors noted. Under the deal, Washington will allow EU countries duty free access for steel and aluminum exports to the United States in volumes comparable to those shipped before tariffs imposed by former President Donald Trump's administration in 2018. In response, the EU removed retaliatory tariffs on U.S. products including whiskey, power boats and Harley-Davidson (HOG) motorcycles. Publicly traded companies in the space include AK Steel (AKS), ArcelorMittal (MT), Nucor (NUE), Steel Dynamics (STLD), TimkenSteel (TMST) and U.S. Steel (X). 2. Moderna (MRNA) provided an update that the U.S. Food and Drug Administration has notified the company that it will require additional time to complete its assessment of Moderna's Emergency Use Authorization request for the use of the Moderna COVID-19 vaccine at the 100 microgram dose level in adolescents 12 to 17 years of age. On Friday evening, the FDA informed Moderna that the agency requires additional time to evaluate recent international analyses of the risk of myocarditis after vaccination. The FDA notified Moderna that this review may not be completed before January 2022. Moderna will delay filing a request for EUA of mRNA-1273 at the 50 microgram dose level in the pediatric population while the FDA completes its review of the adolescent EUA request. 3. Ford (F) has big plans to win the battle for battery supremacy, but it's not the only one, with General Motors (GM) also planning to spend $35B on vehicle electrification by 2025 and Volkswagen (VWAGY) planning to build six battery facilities in Europe by 2030, Al Root wrote in this week's edition of Barron's. Tesla (TSLA), with a big lead over the legacy auto makers, is still investing in battery capacity and technology, the author noted. Auto manufacturers know that the industry has to grow battery capacity fourfold by the middle of the 2020s to meet companies' announced EV goals. Battery manufacturing also has to get much more efficient to bring down the costs, the publication added. 4. AT&T (T) subsidiary Warner Bros.' "Dune" won the domestic box office with a strong $40.1M debut despite its dual release as it opened simultaneously in 4,125 theaters across North America and on streamer HBO Max. Globally, the movie moved past the $100M mark after opening previously in earlier markets. "Dune" grossed another $47.4M from 75 markets overseas for a foreign cume of $180.6M and $220.2M globally. 5. Madison Square Garden Sports (MSGS), MSG Entertainment (MSGE), AMC Networks (AMCX), Sonos (SONO), Cinemark (CNK) and Siemens (SIEGY) saw positive mentions in this week's edition of Barron's.

15:48 EDT Brown-Forman issues statement on U.S.-EU trade agreement - Brown-Forman said in a statement that it "applauds the Biden Administration for today's announcement between the U.S. and the EU regarding steel and aluminum tariffs. This agreement delivers on the Administration's promise to rebuild the Transatlantic alliance by removing tariffs on American whiskey and other U.S. exports, which have been in place now for more than three years. Brown-Forman looks forward to the return of a level playing field on January 1, 2022, and continued international growth for American Whiskey. We hope a similar outcome can soon be achieved between the U.S. and the UK."

15:33 EDT Moderna says FDA needs more time to complete review of COVID-19 shot for teens - Moderna provided an update that the U.S. Food and Drug Administration has notified the company that it will require additional time to complete its assessment of Moderna's Emergency Use Authorization request for the use of the Moderna COVID-19 vaccine at the 100 microgram dose level in adolescents 12 to 17 years of age. On Friday evening, the FDA informed Moderna that the agency requires additional time to evaluate recent international analyses of the risk of myocarditis after vaccination. The FDA notified Moderna that this review may not be completed before January 2022. The safety of vaccine recipients is of paramount importance to Moderna. The Company is fully committed to working closely with the FDA to support their review and is grateful to the FDA for their diligence. An increased risk of myocarditis has been described for COVID-19 vaccines, including the Moderna COVID-19 vaccine, particularly in young men and following the second dose. The U.S. Centers for Disease Control and Prevention and the World Health Organization have stated that myocarditis following vaccination with mRNA vaccines has been rare and generally mild. Moderna will delay filing a request for EUA of mRNA-1273 at the 50 microgram dose level in the pediatric population while the FDA completes its review of the adolescent EUA request.

15:27 EDT Teva announced results from pivotal Phase 3 RISE study - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced results from the pivotal Phase 3 Risperidone Subcutaneous Extended-release study comparing TV-46000/mdc-IRM once monthly and TV-46000/mdc-IRM once every two months with placebo in patients with schizophrenia who underwent stabilization on oral risperidone. Results showed treatment with TV-46000 significantly prolonged time to relapse, decreased proportions of patients with impending relapse at week 24 and demonstrated significant increase in proportions maintaining stability. The safety profile of TV-46000, as demonstrated in this study, is consistent with other formulations of risperidone. The most common adverse reactions were nasopharyngitis, increased weight, and extrapyramidal disorder. These findings, among others, were presented during the poster session at the 2021 Psych Congress Annual Meeting taking place Oct. 29-Nov. 1, 2021 in San Antonio, TX.

15:04 EDT Canadian Pacific, Kansas City Southern file merger application with STB - Canadian Pacific Railway (CP) and Kansas City Southern (KSU) announced they have jointly filed a railroad control application with the Surface Transportation Board regarding the proposed transaction to create Canadian Pacific Kansas City. CP has agreed to acquire KCS in a stock and cash transaction representing an enterprise value of approximately $31 billion, which includes the assumption of $3.8 billion of outstanding KCS debt. The transaction, which has the unanimous support of both boards of directors, values KCS at $300 per share, representing a 34 percent premium, based on the CP closing price on Aug. 9, 2021, the date prior to which CP submitted a revised offer to acquire KCS, and KCS' unaffected closing price on March 19, 2021. The transaction is subject to approval by shareholders of each company along with satisfaction of customary closing conditions, including Mexican regulatory approvals. Shareholders are expected to vote on the transaction later this year. CP's ultimate acquisition of control of KCS' U.S. railways is subject to the approval of the STB. In April 2021, the STB determined it would review the CP-KCS combination under the merger rules in existence prior to 2001 and the waiver granted to KCS in 2001 to exempt it from the 2001 merger rules. In August 2021, the STB reaffirmed that the pre-2001 rules would govern its review of the CP-KCS transaction. On Sept. 30, 2021, the STB confirmed that it has approved the use of a voting trust for the CP-KCS combination. The STB review of CP's proposed control of KCS is expected to be completed in the second half of 2022. Upon obtaining control approval, the two companies will be integrated fully over the ensuing three years, unlocking the benefits of the combination.